Association of the skeletal muscle mass-to-visceral fat area ratio with cardiovascular disease: a cross-sectional study based on NHANES Authors: Ruixue Li, Tianqi Liu, Wei Xin, Zi Liang, Chenguang Zhao, Zinan Zhao, Tian Zhang, Fei Zhao, Wenfeng Xu, Pengfei Jin Published: 2026 ABSTRACT PurposeTo examine the association between the skeletal muscle mass-to-visceral fat area ratio (SVR) and prevalent cardiovascular disease (CVD) in a nationally representative U.S. population.MethodsWe analyzed data from the U.S. National Health and Nutrition Examination Survey (NHANES), 2011–2018. Associations of SVR with composite CVD and its subtypes (heart failure [HF], coronary heart disease [CHD], angina pectoris [AP], myocardial infarction [MI], or stroke) were estimated using multivariable logistic models; linear trend across SVR tertiles was tested, and nonlinearity was assessed using restricted cubic spline (RCS) models. Subgroup analyses assessed heterogeneity.ResultsThe sample comprised 9,997 participants. In multivariable-adjusted logistic models, higher SVR was associated with lower odds of CVD (Model 4: OR = 0.44; 95% CI 0.29–0.67; P < 0.001), with a dose–response (P for trend = 0.001). In subtype analyses, the highest SVR category was associated with lower odds of HF (OR = 0.42, 95% CI 0.18–0.96; P = 0.047), CHD (OR = 0.28, 95% CI 0.11–0.71; P = 0.011), and MI (OR = 0.33, 95% CI 0.11–0.94; P = 0.045), with significant trends for all three outcomes (P for trend < 0.05). RCS models showed nonlinear associations of SVR with composite CVD, CHD, and MI, but not with HF, stroke or AP. Subgroup analyses detected interactions for poverty-income ratio (PIR) and BMI strata (both P for interaction = 0.005).ConclusionHigher SVR may be a potential CVD risk marker, whereas associations with AP and stroke were weak or non-significant. Prospective validation is warranted.Level of evidence: Level V—cross-sectional observational study.Supplementary InformationThe online version contains supplementary material available at 10.1007/s40519-026-01865-1. Introduction Cardiovascular disease (CVD) remains the leading cause of death worldwide and a major source of loss of healthy life years. Although established behavioral and metabolic risk factors, including hypertension, dyslipidemia, diabetes, tobacco use, and unhealthy diet, are well characterized, growing evidence highlights additional determinants, particularly body fat distribution and skeletal muscle mass [1–3]. Visceral adiposity has been closely linked to impaired glucose tolerance, insulin resistance, and other metabolic disturbances, which have been associated with CVD incidence, progression, and prognosis [4, 5]. By contrast, higher skeletal muscle mass has been associated with more favorable cardiometabolic profiles, characterized by better glycemic control and attenuated inflammation [6–9]. Clinical studies have reported that individuals with CVD have lower skeletal muscle mass than healthy controls [7, 8]. Among patients undergoing transcatheter aortic valve implantation, lower psoas muscle mass has been associated with higher 12-month risks of CVD events and mortality [10–12]. Because skeletal muscle and visceral fat may exert opposing effects on metabolic and inflammatory homeostasis, an index integrating both components may better reflect cardiometabolic imbalance than either component alone. In this context, the skeletal muscle mass-to-visceral fat area ratio (SVR) has emerged as a potentially informative body composition-based indicator [13–15]. However, the available literature directly evaluating SVR remains limited. Existing studies have more often focused on metabolic abnormalities, whereas evidence regarding the association between SVR and clinically defined cardiovascular disease remains scarce [16, 17]. In this study, we analyzed data from the National Health and Nutrition Examination Survey (NHANES), in which dual-energy X-ray absorptiometry (DXA) was used to quantify appendicular lean mass (arms and legs) and VFA. We then examined associations between SVR and prevalent CVD and its major subtypes—heart failure (HF), coronary heart disease (CHD), angina pectoris (AP), myocardial infarction (MI), and stroke. Methods Data source This study utilized data from NHANES (https://wwwn.cdc.gov/nchs/nhanes/) collected during 2011–2018. NHANES is a nationally representative, continuous surveillance program administered by the National Center for Health Statistics (NCHS) under the Centers for Disease Control and Prevention (CDC). Employing a complex, multistage, stratified probability sampling design, it yields estimates representative of the U.S. civilian, noninstitutionalized population. Specifically, it integrates standardized questionnaires, physical examinations, laboratory measurements, and dietary surveys to collect comprehensive health and nutrition information. This multifaceted approach enables the assessment of dietary intake, chronic disease prevalence, behavioral risk factors, and environmental exposures. NHANES serves as a foundational resource for public health monitoring, policy-making, and epidemiological research. Study population This cross-sectional study examined the association between SVR and CVD. Participants were excluded based on the following criteria: (1) age < 20 years (n = 16,539); (2) missing DXA measures required to calculate SVR (n = 11,874) or missing CVD status (n = 25); and (3) missing data in key covariates (n = 712 in total). The final analytic sample comprised 9,997 adults. Participant flow is shown in Fig. 1.Fig. 1Participant selection flowchart for NHANES 2011–2018 Participant selection flowchart for NHANES 2011–2018 DXA measurements and SVR calculation Whole-body DXA scans were performed in participants aged 8–59 years, excluding pregnant individuals, those who had used radiographic contrast agents (e.g., barium) within the past 7 days, and those exceeding the DXA table limitations (weight > 450 lbs or height > 6 ft 5 in). All DXA examinations were conducted by trained and certified radiology technologists, with rigorous quality control maintained throughout the entire process to ensure accuracy. Visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) were evaluated using Hologic APEX software, with measures of fat area, mass, and volume at the intervertebral level between L4 and L5. Appendicular skeletal muscle mass (ASM) was calculated as the sum of lean mass in the arms and legs, and SVR was defined as ASM divided by VFA (kg/cm2) [18]. Cardiovascular disease ascertainment CVD was ascertained from self-reported physician diagnoses collected via a standardized medical condition questionnaire. Participants were queried about prior diagnoses of HF, CHD, AP, MI, or stroke; those reporting any of these conditions were classified as having CVD [19]. Definition of covariates The covariates collected in this study encompassed demographic characteristics (age, sex, race, education level, poverty-income ratio [PIR], and marital status), lifestyle factors (smoking status, alcohol consumption, physical activity level, total energy intake, and body mass index [BMI]), and medical comorbidities (hypertension, diabetes, dyslipidemia, cancer, kidney impairment, and hyperuricemia). Smoking status was classified into three categories: never smokers (smoked fewer than 100 cigarettes in their lifetime), former smokers (smoked at least 100 cigarettes but were not currently smoking), and current smokers (smoked at least 100 cigarettes and continued smoking at the time of the survey). Alcohol consumption was defined as having consumed at least 12 alcoholic beverages in the past 12 months. Hypertension was determined on the basis of any of the following: systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, self-reported physician diagnosis, or current use of antihypertensive medication. Diabetes was identified if participants met one or more of the following criteria: fasting plasma glucose ≥ 126 mg/dL, 2 h plasma glucose ≥ 200 mg/dL, hemoglobin A1c (HbA1c) ≥ 6.5%, self-reported physician diagnosis, or current antidiabetic therapy. Dyslipidemia was considered present if any of the following applied: total cholesterol ≥ 200 mg/dL; triglycerides ≥ 150 mg/dL; low-density lipoprotein cholesterol ≥ 130 mg/dL; high-density lipoprotein cholesterol ≤ 40 mg/dL (men) or ≤ 50 mg/dL (women); or current use of lipid-lowering medication. Kidney impairment was defined as a urinary albumin-to-creatinine ratio ≥ 30 mg/g. Physical activity was categorized into high and low levels, according to a previously validated method [20]. Statistical analysis All statistical analyses were conducted using sample weights to account for the complex survey design of NHANES and to ensure nationally representative estimates. Specifically, the 2-year MEC examination weight (WTMEC2YR) was applied as the sampling weight, SDMVSTRA was used as the stratification variable, and SDMVPSU as the primary sampling unit [21]. Detailed information on the weighting strategy is available on the official CDC website (https://wwwn.cdc.gov/nchs/nhanes/analyticguidelines.aspx#sample-design). Incorporating these design elements ensured that the estimates, standard errors (SEs), and 95% confidence intervals appropriately reflected the U.S. non-institutionalized civilian population [22]. Descriptive statistics were used to summarize the baseline demographic and clinical characteristics of the study population. Missing data were handled as follows: (1) participants with missing values in the primary exposure or outcome variables were excluded; (2) for covariates, if the proportion of missingness was < 5%, those observations were deleted; if > 5%, multiple imputation was employed—predictive mean matching (PMM) was used for continuous variables, and logistic regression imputation for categorical variables. For normally distributed continuous variables, results were presented as mean ± SE, and group comparisons were conducted using one-way analysis of variance (ANOVA). For non-normally distributed continuous variables, data were reported as median (Q1, Q3), and comparisons were performed using the Kruskal–Wallis rank-sum test. Categorical variables were expressed as frequencies (percentages), and differences between groups were assessed using the chi-square test or Fisher’s exact test, as appropriate. Statistical significance was defined as P < 0.05. To evaluate the association between SVR and CVD, we fitted four multivariable logistic regression models with increasingly comprehensive covariate adjustment: Model 1, unadjusted; Model 2, adjusted for sex, age, race, PIR, marital status, and education level; Model 3, additionally adjusted for BMI, smoking status, alcohol consumption, physical activity, and total energy intake; and Model 4, further adjusted for hypertension, diabetes, dyslipidemia, serum uric acid, renal impairment, and cancer. The same modeling framework was applied to individual outcomes, including HF, CHD, AP, MI, and stroke. Tests for linear trends across SVR tertiles were conducted using median values of each category as a continuous variable. Potential nonlinearity in the SVR–CVD association was examined using restricted cubic splines (RCS) based on the covariate set in Model 4. Subgroup analyses were conducted across strata defined by age, sex, education level, PIR, BMI, smoking status, alcohol consumption, and histories of hypertension, diabetes, and dyslipidemia, with interaction tests performed to evaluate effect modification and support the robustness of the findings. Results Baseline characteristics of participants across SVR tertiles Baseline characteristics of 9,997 participants were summarized by tertiles of SVR (T1–T3), among whom 378 were diagnosed with cardiovascular disease. Demographic and clinical profiles differed significantly across SVR tertiles (Table 1). Relative to T1, participants in T3 were younger, more often male and non-Hispanic Black, and had a higher education level. T3 also had higher energy intake, lower BMI, lower smoking prevalence, and higher physical activity levels. In addition, T3 showed lower prevalence of hypertension, diabetes, dyslipidemia, and renal impairment, along with lower serum uric acid levels. Conversely, CVD prevalence was higher in T1. Table 1Weighted baseline characteristics of participantsVariableSVR (kg/cm2)OverallT1 (≤ 0.20)T2 (0.2–0.34)T3 (≥ 0.34)P-valueAge, y, n (%) < 0.001* < 456351 (62.46)1401 (40.28)2237 (63.66)2713 (83.37) ≥ 453646 (37.54)1950 (59.72)1206 (36.34)490 (16.63)Sex, n (%) < 0.001* Male4941 (50.35)1134 (37.42)1874 (54.40)1933 (59.09) Female5056 (49.65)2217 (62.58)1569 (45.60)1270 (40.91)Race, n (%) < 0.001* Mexican American1484 (10.44)767 (14.35)514 (11.46)203 (5.47) Other Hispanic1060 (7.53)436 (8.21)355 (7.64)269 (6.73) Non-Hispanic White3468 (61.35)1213 (63.56)1129 (59.00)1126 (61.57) Non-Hispanic Black2088 (11.11)350 (5.27)727 (11.17)1011 (16.88) Other Race1897 (9.58)585 (8.61)718 (10.73)594 (9.36)Marital status, n (%) < 0.001* Divorced/Separated/Widowed1406 (13.26)646 (18.82)471 (12.81)289 (8.17) Married/Living with a partner5996 (62.28)2248 (68.13)2179 (66.20)1569 (52.39) Never married2595 (24.46)457 (13.04)793 (20.99)1345 (39.44)Education levels, n (%) < 0.001* High school and below3961 (34.27)1564 (40.17)1346 (34.86)1051 (27.78) Above high school6036 (65.73)1787 (59.83)2097 (65.14)2152 (72.22)PIR, n (%)0.281 < 1.33286 (23.97)1215 (25.52)1064 (22.34)1007 (24.10) 1.3–3.53605 (34.20)1180 (34.03)1245 (34.51)1180 (34.04) > 3.53106 (41.84)956 (40.45)1134 (43.15)1016 (41.86)BMI, n (%) < 0.001* < 253189 (31.80)399 (9.90)899 (24.90)1891 (60.77) 25–29.993194 (32.99)1104 (32.75)1284 (39.57)806 (26.45) ≥ 303614 (35.21)1848 (57.35)1260 (35.53)506 (12.78)Smoking status, n (%) < 0.001* Never6114 (59.05)1997 (55.01)2135 (59.75)1982 (62.36) Former1675 (19.59)665 (23.86)583 (19.27)427 (15.65) Now2208 (21.36)689 (21.13)725 (20.98)794 (21.98)Alcohol consumption, n (%) < 0.001* No2531 (18.84)1075 (22.99)797 (18.05)659 (15.51) Yes7466 (81.16)2276 (77.01)2646 (81.95)2544 (84.49)Physical activity level, n (%): < 0.001* Low3054 (27.75)1424 (39.95)1011 (27.31)619 (16.01) High6943 (72.25)1927 (60.05)2432 (72.69)2584 (83.99)Energy intake, median (Q1, Q3)2058.50 (1589.00, 2626.00)1936.00 (1504.50, 2481.00)2076.00 (1593.00, 2631.00)2173.50 (1668.00, 2783.50) < 0.001*Hypertension, n (%) < 0.001* No7252 (73.79)2011 (59.98)2514 (74.66)2727 (86.69) Yes2745 (26.21)1340 (40.02)929 (25.34)476 (13.31)Diabetes, n (%) < 0.001* No8878 (91.48)2624 (82.91)3140 (93.23)3114 (98.22) Yes1119 (8.52)727 (17.09)303 (6.77)89 (1.78)Dyslipidemia, n (%) < 0.001* No3751 (37.78)608 (17.99)1199 (34.42)1944 (60.99) Yes6246 (62.22)2743 (82.01)2244 (65.58)1259 (39.01)CVD, n (%) < 0.001* No9619 (96.89)3135 (94.05)3333 (97.72)3151 (98.85) Yes378 (3.11)216 (5.95)110 (2.28)52 (1.15)HF, n (%) < 0.001* No9898 (99.28)3292 (98.55)3415 (99.46)3191 (99.81) Yes96 (0.71)57 (1.41)28 (0.54)11 (0.19) Don't know3 (0.01)2 (0.04)0 (0.00)1 (0.01)CHD, n (%) < 0.001* No9898 (99.03)3285 (97.90)3421 (99.39)3192 (99.80) Yes96 (0.90)63 (1.91)22 (0.61)11 (0.20) Don't know3 (0.06)3 (0.20)0 (0.00)0 (0.00)AP, n (%) < 0.001* No9898 (99.14)3290 (98.38)3419 (99.36)3189 (99.68) Yes94 (0.83)59 (1.59)23 (0.63)12 (0.30) Don't know5 (0.03)2 (0.04)1 (0.02)2 (0.03)MI, n (%) < 0.001* No9860 (98.82)3267 (97.60)3406 (99.17)3187 (99.68) Yes135 (1.17)83 (2.38)37 (0.83)15 (0.31) Don't know2 (0.01)1 (0.01)0 (0.00)1 (0.01)Stroke, n (%) < 0.001* No9853 (98.93)3272 (98.20)3403 (99.24)3178 (99.34) Yes144 (1.07)79 (1.80)40 (0.76)25 (0.66)Cancer, n (%) < 0.001* No9632 (95.18)3160 (92.59)3340 (96.06)3132 (96.85) Yes362 (4.78)189 (7.29)102 (3.93)71 (3.15) Don't know3 (0.04)2 (0.12)1 (0.01)0 (0.00)Renal impairment, n (%) < 0.001* No9197 (93.37)2969 (90.75)3197 (94.42)3031 (94.90) Yes800 (6.63)382 (9.25)246 (5.58)172 (5.10)Uric acid, mean (SE)315.93 (1.24)323.30 (1.93)320.45 (1.78)303.91 (1.86) < 0.001*Continuous variables are presented as means (standard errors) to indicate the precision of the estimates; variables with skewed distributions as medians (Q1, Q3); and categorical variables as n (weighted percentages)SVR skeletal muscle mass to visceral fat area ratio, PIR poverty income ratio, BMI body mass index, CVD cardiovascular disease, HF heart failure, CHD coronary heart disease, AP angina pectoris, MI myocardial infarction*A statistically significant difference is found (P < 0.05)aKruskal–Wallis tests for continuous variables; Chi-squared tests for categorical variablesbMean (SE) for continuous variables; median (Q1, Q3) for skewed variables; and n (weighted percentages) for categorical variables Table 1Weighted baseline characteristics of participantsVariableSVR (kg/cm2)OverallT1 (≤ 0.20)T2 (0.2–0.34)T3 (≥ 0.34)P-valueAge, y, n (%) < 0.001* < 456351 (62.46)1401 (40.28)2237 (63.66)2713 (83.37) ≥ 453646 (37.54)1950 (59.72)1206 (36.34)490 (16.63)Sex, n (%) < 0.001* Male4941 (50.35)1134 (37.42)1874 (54.40)1933 (59.09) Female5056 (49.65)2217 (62.58)1569 (45.60)1270 (40.91)Race, n (%) < 0.001* Mexican American1484 (10.44)767 (14.35)514 (11.46)203 (5.47) Other Hispanic1060 (7.53)436 (8.21)355 (7.64)269 (6.73) Non-Hispanic White3468 (61.35)1213 (63.56)1129 (59.00)1126 (61.57) Non-Hispanic Black2088 (11.11)350 (5.27)727 (11.17)1011 (16.88) Other Race1897 (9.58)585 (8.61)718 (10.73)594 (9.36)Marital status, n (%) < 0.001* Divorced/Separated/Widowed1406 (13.26)646 (18.82)471 (12.81)289 (8.17) Married/Living with a partner5996 (62.28)2248 (68.13)2179 (66.20)1569 (52.39) Never married2595 (24.46)457 (13.04)793 (20.99)1345 (39.44)Education levels, n (%) < 0.001* High school and below3961 (34.27)1564 (40.17)1346 (34.86)1051 (27.78) Above high school6036 (65.73)1787 (59.83)2097 (65.14)2152 (72.22)PIR, n (%)0.281 < 1.33286 (23.97)1215 (25.52)1064 (22.34)1007 (24.10) 1.3–3.53605 (34.20)1180 (34.03)1245 (34.51)1180 (34.04) > 3.53106 (41.84)956 (40.45)1134 (43.15)1016 (41.86)BMI, n (%) < 0.001* < 253189 (31.80)399 (9.90)899 (24.90)1891 (60.77) 25–29.993194 (32.99)1104 (32.75)1284 (39.57)806 (26.45) ≥ 303614 (35.21)1848 (57.35)1260 (35.53)506 (12.78)Smoking status, n (%) < 0.001* Never6114 (59.05)1997 (55.01)2135 (59.75)1982 (62.36) Former1675 (19.59)665 (23.86)583 (19.27)427 (15.65) Now2208 (21.36)689 (21.13)725 (20.98)794 (21.98)Alcohol consumption, n (%) < 0.001* No2531 (18.84)1075 (22.99)797 (18.05)659 (15.51) Yes7466 (81.16)2276 (77.01)2646 (81.95)2544 (84.49)Physical activity level, n (%): < 0.001* Low3054 (27.75)1424 (39.95)1011 (27.31)619 (16.01) High6943 (72.25)1927 (60.05)2432 (72.69)2584 (83.99)Energy intake, median (Q1, Q3)2058.50 (1589.00, 2626.00)1936.00 (1504.50, 2481.00)2076.00 (1593.00, 2631.00)2173.50 (1668.00, 2783.50) < 0.001*Hypertension, n (%) < 0.001* No7252 (73.79)2011 (59.98)2514 (74.66)2727 (86.69) Yes2745 (26.21)1340 (40.02)929 (25.34)476 (13.31)Diabetes, n (%) < 0.001* No8878 (91.48)2624 (82.91)3140 (93.23)3114 (98.22) Yes1119 (8.52)727 (17.09)303 (6.77)89 (1.78)Dyslipidemia, n (%) < 0.001* No3751 (37.78)608 (17.99)1199 (34.42)1944 (60.99) Yes6246 (62.22)2743 (82.01)2244 (65.58)1259 (39.01)CVD, n (%) < 0.001* No9619 (96.89)3135 (94.05)3333 (97.72)3151 (98.85) Yes378 (3.11)216 (5.95)110 (2.28)52 (1.15)HF, n (%) < 0.001* No9898 (99.28)3292 (98.55)3415 (99.46)3191 (99.81) Yes96 (0.71)57 (1.41)28 (0.54)11 (0.19) Don't know3 (0.01)2 (0.04)0 (0.00)1 (0.01)CHD, n (%) < 0.001* No9898 (99.03)3285 (97.90)3421 (99.39)3192 (99.80) Yes96 (0.90)63 (1.91)22 (0.61)11 (0.20) Don't know3 (0.06)3 (0.20)0 (0.00)0 (0.00)AP, n (%) < 0.001* No9898 (99.14)3290 (98.38)3419 (99.36)3189 (99.68) Yes94 (0.83)59 (1.59)23 (0.63)12 (0.30) Don't know5 (0.03)2 (0.04)1 (0.02)2 (0.03)MI, n (%) < 0.001* No9860 (98.82)3267 (97.60)3406 (99.17)3187 (99.68) Yes135 (1.17)83 (2.38)37 (0.83)15 (0.31) Don't know2 (0.01)1 (0.01)0 (0.00)1 (0.01)Stroke, n (%) < 0.001* No9853 (98.93)3272 (98.20)3403 (99.24)3178 (99.34) Yes144 (1.07)79 (1.80)40 (0.76)25 (0.66)Cancer, n (%) < 0.001* No9632 (95.18)3160 (92.59)3340 (96.06)3132 (96.85) Yes362 (4.78)189 (7.29)102 (3.93)71 (3.15) Don't know3 (0.04)2 (0.12)1 (0.01)0 (0.00)Renal impairment, n (%) < 0.001* No9197 (93.37)2969 (90.75)3197 (94.42)3031 (94.90) Yes800 (6.63)382 (9.25)246 (5.58)172 (5.10)Uric acid, mean (SE)315.93 (1.24)323.30 (1.93)320.45 (1.78)303.91 (1.86) < 0.001*Continuous variables are presented as means (standard errors) to indicate the precision of the estimates; variables with skewed distributions as medians (Q1, Q3); and categorical variables as n (weighted percentages)SVR skeletal muscle mass to visceral fat area ratio, PIR poverty income ratio, BMI body mass index, CVD cardiovascular disease, HF heart failure, CHD coronary heart disease, AP angina pectoris, MI myocardial infarction*A statistically significant difference is found (P < 0.05)aKruskal–Wallis tests for continuous variables; Chi-squared tests for categorical variablesbMean (SE) for continuous variables; median (Q1, Q3) for skewed variables; and n (weighted percentages) for categorical variables Weighted baseline characteristics of participants Continuous variables are presented as means (standard errors) to indicate the precision of the estimates; variables with skewed distributions as medians (Q1, Q3); and categorical variables as n (weighted percentages) SVR skeletal muscle mass to visceral fat area ratio, PIR poverty income ratio, BMI body mass index, CVD cardiovascular disease, HF heart failure, CHD coronary heart disease, AP angina pectoris, MI myocardial infarction *A statistically significant difference is found (P < 0.05) aKruskal–Wallis tests for continuous variables; Chi-squared tests for categorical variables bMean (SE) for continuous variables; median (Q1, Q3) for skewed variables; and n (weighted percentages) for categorical variables Association between SVR and cardiovascular disease Table 2 presents multivariable logistic regression estimates for the associations of SVR tertiles with composite CVD and its subtypes (HF, CHD, MI, AP, and stroke); P for trend across tertiles was evaluated in a series of progressively adjusted models. The results demonstrated a significant inverse association between SVR and the prevalence of composite CVD. Compared with the lowest tertile (T1, SVR ≤ 0.20), individuals in both the intermediate tertile (T2, SVR = 0.20–0.34) and the highest tertile (T3, SVR > 0.34) had lower odds of CVD, although the associations were attenuated after progressive adjustment. In the fully adjusted model (Model 4), the odds ratios for T2 and T3 were 0.57 (95% CI 0.38–0.86; P = 0.012) and 0.44 (95% CI 0.29–0.67; P < 0.001), respectively, with a significant dose–response trend across SVR tertiles (P for trend = 0.001). Table 2Multivariable logistic regression analyses assessing the associations of SVR with CVD, HF, CHD, AP, MI, and strokeModel 1Model 2Model 3Model 4OR (95% CI)p-valueOR (95% CI)p-valueOR (95% CI)p-valueOR (95% CI)p-valueCVD SVR tertile T1 (≤ 0.20)1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference) T2 (0.20–0.34)0.37 (0.25 ~ 0.53) < 0.001*0.43 (0.29 ~ 0.66) < 0.001*0.49 (0.33 ~ 0.73) < 0.001*0.57 (0.38 ~ 0.86)0.012* T3 (≥ 0.34)0.18 (0.13 ~ 0.27) < 0.001*0.25 (0.16 ~ 0.40) < 0.001*0.33 (0.21 ~ 0.52) < 0.001*0.44 (0.29 ~ 0.67) < 0.001* P for trend < 0.001* < 0.001* < 0.001*0.001*HF SVR tertile T1 (≤ 0.20)1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference) T2 (0.20–0.34)0.38 (0.19 ~ 0.76)0.008*0.42 (0.18 ~ 0.98)0.049*0.52 (0.25 ~ 1.07)0.0830.68 (0.31 ~ 1.48)0.340 T3 (≥ 0.34)0.13 (0.06 ~ 0.28) < 0.001*0.16 (0.07 ~ 0.38) < 0.001*0.24 (0.10 ~ 0.58)0.003*0.42 (0.18 ~ 0.96)0.048* P for trend < 0.001* < 0.001*0.003*0.047*CHD SVR tertile T1 (≤ 0.20)1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference) T2 (0.20–0.34)0.31 (0.14 ~ 0.69)0.005*0.38 (0.15 ~ 0.95)0.043*0.43 (0.20 ~ 0.95)0.043*0.50 (0.22 ~ 1.13)0.104 T3 (≥ 0.34)0.10 (0.05 ~ 0.23) < 0.001*0.16 (0.05 ~ 0.47)0.002*0.18 (0.07 ~ 0.48)0.001*0.28 (0.11 ~ 0.71)0.011* P for trend < 0.001*0.006*0.002*0.016*AP SVR tertile T1 (≤ 0.20)1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference) T2 (0.20–0.34)0.39 (0.19 ~ 0.79)0.011*0.54 (0.24 ~ 1.18)0.1290.59 (0.30 ~ 1.16)0.1330.68 (0.33 ~ 1.40)0.307 T3 (≥ 0.34)0.18 (0.08 ~ 0.44) < 0.001*0.33 (0.13 ~ 0.80)0.019*0.39 (0.19 ~ 0.82)0.017*0.50 (0.21 ~ 1.21)0.132 P for trend < 0.001*0.028*0.021*0.133MI SVR tertile T1 (≤ 0.20)1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference) T2 (0.20–0.34)0.34 (0.21 ~ 0.57) < 0.001*0.44 (0.25 ~ 0.76)0.005*0.48 (0.28 ~ 0.83)0.012*0.57 (0.32 ~ 1.02)0.065 T3 (≥ 0.34)0.13 (0.05 ~ 0.32) < 0.001*0.21 (0.07 ~ 0.62)0.007*0.24 (0.08 ~ 0.77)0.020*0.33 (0.11 ~ 0.94)0.045* P for trend < 0.001*0.007*0.020*0.044*Stroke SVR tertile T1 (≤ 0.20)1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference) T2 (0.20–0.34)0.42 (0.24 ~ 0.72)0.003*0.55 (0.29 ~ 1.03)0.0670.56 (0.31 ~ 1.01)0.0620.64 (0.34 ~ 1.19)0.164 T3 (≥ 0.34)0.36 (0.21 ~ 0.64) < 0.001*0.60 (0.27 ~ 1.32)0.2070.60 (0.28 ~ 1.26)0.1840.79 (0.41 ~ 1.53)0.492 P for trend0.003*0.2450.2350.550Model 1 was unadjustedModel 2 was adjusted for age, sex, race, PIR, education level, marital statusModel 3 was adjusted for age, sex, race, PIR, education level, marital status, smoking status, alcohol consumption, physical activity level, BMI, energy intakeModel 4 was adjusted for age, sex, race, PIR, education level, marital status, smoking status, alcohol consumption, physical activity level, BMI, energy intake, cancer, hypertension, diabetes, dyslipidemia, renal impairment, uric acidSVR skeletal muscle mass to visceral fat area ratio, PIR poverty income ratio, BMI body mass index, CVD cardiovascular disease, HF heart failure, CHD coronary heart disease, AP angina pectoris, MI myocardial infarction, OR odds ratio, 95% CI 95% confidence interval*A statistically significant result is detected Table 2Multivariable logistic regression analyses assessing the associations of SVR with CVD, HF, CHD, AP, MI, and strokeModel 1Model 2Model 3Model 4OR (95% CI)p-valueOR (95% CI)p-valueOR (95% CI)p-valueOR (95% CI)p-valueCVD SVR tertile T1 (≤ 0.20)1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference) T2 (0.20–0.34)0.37 (0.25 ~ 0.53) < 0.001*0.43 (0.29 ~ 0.66) < 0.001*0.49 (0.33 ~ 0.73) < 0.001*0.57 (0.38 ~ 0.86)0.012* T3 (≥ 0.34)0.18 (0.13 ~ 0.27) < 0.001*0.25 (0.16 ~ 0.40) < 0.001*0.33 (0.21 ~ 0.52) < 0.001*0.44 (0.29 ~ 0.67) < 0.001* P for trend < 0.001* < 0.001* < 0.001*0.001*HF SVR tertile T1 (≤ 0.20)1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference) T2 (0.20–0.34)0.38 (0.19 ~ 0.76)0.008*0.42 (0.18 ~ 0.98)0.049*0.52 (0.25 ~ 1.07)0.0830.68 (0.31 ~ 1.48)0.340 T3 (≥ 0.34)0.13 (0.06 ~ 0.28) < 0.001*0.16 (0.07 ~ 0.38) < 0.001*0.24 (0.10 ~ 0.58)0.003*0.42 (0.18 ~ 0.96)0.048* P for trend < 0.001* < 0.001*0.003*0.047*CHD SVR tertile T1 (≤ 0.20)1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference) T2 (0.20–0.34)0.31 (0.14 ~ 0.69)0.005*0.38 (0.15 ~ 0.95)0.043*0.43 (0.20 ~ 0.95)0.043*0.50 (0.22 ~ 1.13)0.104 T3 (≥ 0.34)0.10 (0.05 ~ 0.23) < 0.001*0.16 (0.05 ~ 0.47)0.002*0.18 (0.07 ~ 0.48)0.001*0.28 (0.11 ~ 0.71)0.011* P for trend < 0.001*0.006*0.002*0.016*AP SVR tertile T1 (≤ 0.20)1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference) T2 (0.20–0.34)0.39 (0.19 ~ 0.79)0.011*0.54 (0.24 ~ 1.18)0.1290.59 (0.30 ~ 1.16)0.1330.68 (0.33 ~ 1.40)0.307 T3 (≥ 0.34)0.18 (0.08 ~ 0.44) < 0.001*0.33 (0.13 ~ 0.80)0.019*0.39 (0.19 ~ 0.82)0.017*0.50 (0.21 ~ 1.21)0.132 P for trend < 0.001*0.028*0.021*0.133MI SVR tertile T1 (≤ 0.20)1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference) T2 (0.20–0.34)0.34 (0.21 ~ 0.57) < 0.001*0.44 (0.25 ~ 0.76)0.005*0.48 (0.28 ~ 0.83)0.012*0.57 (0.32 ~ 1.02)0.065 T3 (≥ 0.34)0.13 (0.05 ~ 0.32) < 0.001*0.21 (0.07 ~ 0.62)0.007*0.24 (0.08 ~ 0.77)0.020*0.33 (0.11 ~ 0.94)0.045* P for trend < 0.001*0.007*0.020*0.044*Stroke SVR tertile T1 (≤ 0.20)1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference) T2 (0.20–0.34)0.42 (0.24 ~ 0.72)0.003*0.55 (0.29 ~ 1.03)0.0670.56 (0.31 ~ 1.01)0.0620.64 (0.34 ~ 1.19)0.164 T3 (≥ 0.34)0.36 (0.21 ~ 0.64) < 0.001*0.60 (0.27 ~ 1.32)0.2070.60 (0.28 ~ 1.26)0.1840.79 (0.41 ~ 1.53)0.492 P for trend0.003*0.2450.2350.550Model 1 was unadjustedModel 2 was adjusted for age, sex, race, PIR, education level, marital statusModel 3 was adjusted for age, sex, race, PIR, education level, marital status, smoking status, alcohol consumption, physical activity level, BMI, energy intakeModel 4 was adjusted for age, sex, race, PIR, education level, marital status, smoking status, alcohol consumption, physical activity level, BMI, energy intake, cancer, hypertension, diabetes, dyslipidemia, renal impairment, uric acidSVR skeletal muscle mass to visceral fat area ratio, PIR poverty income ratio, BMI body mass index, CVD cardiovascular disease, HF heart failure, CHD coronary heart disease, AP angina pectoris, MI myocardial infarction, OR odds ratio, 95% CI 95% confidence interval*A statistically significant result is detected Multivariable logistic regression analyses assessing the associations of SVR with CVD, HF, CHD, AP, MI, and stroke Model 1 was unadjusted Model 2 was adjusted for age, sex, race, PIR, education level, marital status Model 3 was adjusted for age, sex, race, PIR, education level, marital status, smoking status, alcohol consumption, physical activity level, BMI, energy intake Model 4 was adjusted for age, sex, race, PIR, education level, marital status, smoking status, alcohol consumption, physical activity level, BMI, energy intake, cancer, hypertension, diabetes, dyslipidemia, renal impairment, uric acid SVR skeletal muscle mass to visceral fat area ratio, PIR poverty income ratio, BMI body mass index, CVD cardiovascular disease, HF heart failure, CHD coronary heart disease, AP angina pectoris, MI myocardial infarction, OR odds ratio, 95% CI 95% confidence interval *A statistically significant result is detected In subtype analyses, SVR was inversely associated with HF, CHD, and MI. In the fully adjusted model (Model 4), T3 versus T1 ORs were 0.42 (95% CI 0.18–0.96; P = 0.047) for HF, 0.28 (95% CI 0.11–0.71; P = 0.011) for CHD, and 0.33 (95% CI 0.11–0.94; P = 0.045) for MI; P for trend across tertiles was significant for all three outcomes. Notably, the statistical significance of the T2 group was attenuated after full adjustment, suggesting that the inverse association of SVR may be more pronounced at higher levels (T3); at intermediate levels (T2), the direction was consistent but the evidence was insufficient. For AP, the inverse association observed in minimally adjusted models remained in direction but was not statistically significant after full adjustment. Stroke showed a similar pattern: an initial inverse trend that failed to reach statistical significance in the final model. Overall, higher SVR was inversely associated with composite CVD and major subtypes—particularly HF, CHD, and MI—in multivariable models, with significant dose–response trends across tertiles. SVR-based RCS analysis for CVD Figure 2 illustrates the RCS results for the association between SVR and composite CVD. Corresponding RCS analyses for HF, CHD, AP, MI, and stroke are presented in Supplementary Figs. S1–S5, respectively. All RCS analyses were fitted using the fully adjusted model (Model 4). The results revealed significant nonlinear associations for composite CVD and specific subtypes, particularly CHD and MI, whereas no evidence of nonlinearity was observed for HF, AP, or stroke.Fig. 2RCS model of the association between SVR and CVD. RCS restricted cubic spline, SVR skeletal muscle mass to visceral fat area ratio, CVD cardiovascular disease, OR odds ratio, CI confidence interval RCS model of the association between SVR and CVD. RCS restricted cubic spline, SVR skeletal muscle mass to visceral fat area ratio, CVD cardiovascular disease, OR odds ratio, CI confidence interval Subgroup analyses of SVR in relation to CVD As shown in Fig. 3, the association between SVR and CVD remained statistically significant across most subgroups, with no evidence of interaction in the majority of strata (P for interaction > 0.05), indicating broadly consistent associations across population groups. All analyses were survey-weighted to account for the complex, multistage sampling design and were conducted using multivariable logistic regression. Notably, significant interactions were observed for PIR and BMI (P for interaction = 0.005 for both), suggesting that these factors may modify the SVR–CVD association.Fig. 3Forest plot of subgroup analyses for the association between SVR and CVD. Age, sex, race, PIR, education level, marital status, smoking status, alcohol consumption, physical activity level, BMI, energy intake, cancer, hypertension, diabetes, dyslipidemia, renal impairment, uric acid were adjusted in the subgroup analysis. SVR skeletal muscle mass to visceral fat area ratio, PIR poverty income ratio, BMI body mass index, CVD cardiovascular disease, OR odds ratio, CI confidence interval Forest plot of subgroup analyses for the association between SVR and CVD. Age, sex, race, PIR, education level, marital status, smoking status, alcohol consumption, physical activity level, BMI, energy intake, cancer, hypertension, diabetes, dyslipidemia, renal impairment, uric acid were adjusted in the subgroup analysis. SVR skeletal muscle mass to visceral fat area ratio, PIR poverty income ratio, BMI body mass index, CVD cardiovascular disease, OR odds ratio, CI confidence interval In the subgroup with moderate income (PIR = 1.3–3.5), the association between SVR and CVD was statistically significant (OR < 0.01; 95% CI < 0.01–0.12; P = 0.004). By contrast, no significant associations were observed for PIR < 1.3 (OR = 0.86; 95% CI 0.34–2.15; P = 0.748) or PIR > 3.5 (OR = 0.08; 95% CI < 0.01–4.31; P = 0.214), suggesting a stronger association of SVR with CVD in the middle PIR group. Similarly, in BMI-stratified analyses, the association was not significant for BMI < 25 (OR = 0.81; 95% CI 0.29–2.25; P = 0.693) but was significant for BMI 25–29.9 (OR = 0.03; 95% CI 0.01–0.77; P = 0.034) and BMI ≥ 30 (OR < 0.01; 95% CI < 0.01–0.11; P = 0.002), indicating a stronger association of SVR with CVD among overweight and obese participants. Discussion To our knowledge, few prior studies have directly examined SVR in relation to the prevalence of CVD. In the present cross-sectional analysis, higher SVR was significantly associated with lower odds of composite CVD. Similar inverse associations were also observed for several major subtypes, particularly HF, CHD, and MI, suggesting a potential cardioprotective role of a more favorable muscle-fat distribution. However, these associations were not uniform across all subtype analyses. These results reinforce the beneficial contribution of skeletal muscle mass to cardiovascular health and underscore the detrimental role of visceral adiposity in CVD pathogenesis. Taken together, our findings suggest that SVR may serve as a useful integrated body-composition marker associated with cardiovascular health and highlight the potential importance of overall body composition, especially the balance between skeletal muscle and visceral fat, in understanding CVD burden. These results may be explained by multiple biological mechanisms. The adverse effects of VAT on cardiovascular events have been extensively studied [23, 24]. Compared with subcutaneous adipose tissue, VAT harbors larger adipocytes,adipocyte hypertrophy promotes adipose-tissue dysfunction, and hypertrophic adipocytes exhibit insulin resistance. Insulin resistance can contribute to CVD via endothelial dysfunction, sodium retention, heightened sympathetic activity, and vascular hypertrophy. As a metabolically active tissue, VAT secretes multiple proinflammatory and metabolic mediators, including interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and leptin [13–15]. Elevated circulating leptin concentrations have been shown to predict incident CVD [25, 26], and increases in several proinflammatory cytokines are mechanistically implicated in the development and progression of CVD [27, 28]. Building on this, the role of skeletal muscle in cardiovascular health and overall well-being is equally critical. In a study including 469,830 UK Biobank participants, a slow walking pace and lower muscle mass were associated with a higher incidence of CVD. The pathophysiological mechanisms linking muscle mass with CVD risk and mortality are complex and warrant further investigation. As a principal site of glucose and lipid metabolism, an increase in muscle mass may help stabilize metabolic homeostasis and is associated with multiple health benefits, including enhanced insulin sensitivity, reduced inflammatory levels, and an increased metabolic rate. Chronic systemic inflammation is a key driver of skeletal muscle wasting and declines in muscle quality and is associated with increased risks of CVD and mortality [29]. Moreover, inflammatory and oxidative-stress pathways that impair muscle health overlap with those implicated in CVD, promoting the release of actin from skeletal myocytes and cardiomyocytes and perpetuating a vicious cycle [30]. Consistent with these mechanistic considerations, our results show that a higher SVR, an indicator of greater muscle mass relative to visceral adiposity, is significantly associated with a lower odds of composite CVD,this association remains robust after adjustment for age, BMI, and other potential confounders. These findings highlight the potential importance of considering both visceral adiposity and skeletal muscle mass in relation to cardiovascular health. Prior studies have examined the joint influence of skeletal muscle and visceral adiposity on CVD from an integrated perspective, but the operational definitions and measurement indicators have differed. In a UK-based prospective study (n = 452,931; ages 40–69; mean follow-up, 5.1 years), individuals with sarcopenic obesity (SO), defined by low grip strength together with elevated BMI, had a higher risk of CVD than those with low grip strength alone or obesity alone. In a prospective study of the general Japanese population (n = 2,490), dynapenic obesity (low grip strength plus obesity) was likewise significantly associated with incident CVD [31]. By contrast, a prospective study of British men aged 60–79 years (n = 4,111, mean follow-up, 11.3 years) found that SO defined by mid-upper arm circumference and waist circumference was not significantly associated with CVD risk [32]. Similarly, a community-based U.S. study of older adults (n = 3,366,ages ≥ 65 years) showed that SO was unrelated to CVD risk when defined by skeletal muscle mass and waist circumference; when defined by grip strength and waist circumference, only a borderline statistically significant association was observed [33]. In addition, a cross-sectional study following the definition by Lopes et al. [34] and using the muscle quality index as the measure of muscular status found limited predictive performance for CVD and mortality [2]. Overall, evidence points to an association between composite muscle-fat phenotypes and CVD risk, but findings remain inconsistent owing to divergent SO definitions, metric selection, adiposity assessment methods, and differences in populations and follow-up. To strengthen comparability across studies, it will be important to standardize terminology and adopt harmonized thresholds. In analyses across cardiovascular disease subtypes, we observed that, in fully adjusted models, participants with CHD, HF, or MI had lower SVR than participants without these conditions. Adiposity contributes substantially to the major risk factors for CHD—hypertension, dyslipidemia, and diabetes—and may itself be an independent risk factor for atherosclerosis and incident CHD events [35]. Similarly, an analysis based on NHANES suggested a nonlinear dose–response association between the VAI and CHD [36]. Excess adiposity and ectopic fat deposition upregulate pro-atherogenic inflammatory mediators, increase vascular wall stress, and cause myocardial injury, thereby promoting left ventricular hypertrophy and remodeling; these processes ultimately culminate in diastolic and systolic dysfunction and progression to HF [37]. In addition, obesity increases circulating blood volume and cardiac output requirements, further augmenting volume and pressure overload and thereby exacerbating HF. Sarcopenia may contribute to ventilatory inefficiency and exercise intolerance in patients with congestive heart failure and has been associated with reduced survival in this population. Prior studies have shown that the prevalence of sarcopenia among patients with HF with reduced ejection fraction is approximately 20% higher than in healthy individuals [38], suggesting a bidirectional, mutually reinforcing pathophysiological link between sarcopenia and HF. Excess adiposity may increase the risk of MI through sustained systemic inflammation and its long-term effects on coronary atherosclerosis. Madala et al. reported that overweight was closely associated with a younger age at the first occurrence of non–ST-segment elevation myocardial infarction [39]. Sato et al. further observed that, among patients with ST-segment elevation myocardial infarction, lower skeletal muscle mass was independently associated with a lower left ventricular ejection fraction and an increased risk of major adverse cardiovascular outcomes, including all-cause mortality, nonfatal MI, nonfatal ischemic stroke, hospitalization for HF, and unplanned revascularization [40]. By contrast, the attenuated associations for AP and stroke after full adjustment may reflect heterogeneity across CVD subtypes. In contrast to HF, CHD, and MI, which are more directly linked to adiposity-related atherosclerotic burden, myocardial remodeling, and metabolic dysfunction, AP is a symptom-based and potentially more heterogeneous clinical entity, whereas stroke comprises pathophysiologically distinct subtypes with different risk profiles [41, 42]. In addition, because these outcomes were self-reported, misclassification may have varied across subtypes, which could have further weakened the observed associations. Subgroup analyses revealed significant interactions of BMI and PIR with the association between SVR and CVD. Among individuals who were overweight or obese, the protective association of a higher SVR with CVD appeared more pronounced, underscoring the importance—particularly in higher-BMI groups—of increasing skeletal muscle mass while reducing the burden of visceral adiposity. In addition, the inverse association between SVR and CVD was stronger among participants with intermediate income levels, indicating effect modification by PIR. This pattern may reflect the influence of broader socioeconomic context: in lower-income groups, limited access to healthcare, poorer diet quality, heightened psychosocial stress, and adverse environmental exposures may obscure the benefits associated with higher SVR; whereas in higher-income groups, greater access to health resources, more favorable lifestyle behaviors, and earlier clinical interventions may already lower baseline CVD risk, thereby attenuating the incremental contribution of SVR. Compared with prior research, this study employed SVR as an integrated indicator of body composition and analyzed a large, nationally representative U.S. sample, enabling a comprehensive assessment of the SVR–CVD relationship with extensive covariate adjustment to reduce bias and evaluate robustness. Strengths and limitations This study has several strengths. First, it was based on NHANES, a nationally representative survey with standardized protocols, which enhances the generalizability and reliability of the findings in the U.S. adult population. Second, to our knowledge, this is the first study to examine the association between SVR and CVD. Third, beyond overall CVD, we further evaluated the associations between SVR and specific CVD subtypes, providing a more nuanced understanding of the cardiometabolic relevance of SVR. Fourth, we conducted subgroup analyses and explored potential nonlinear associations, which strengthened the robustness and interpretability of the findings. Nevertheless, several limitations warrant consideration. First, cardiovascular disease was identified based on validated self-reported questionnaires rather than clinical adjudication or medical record review, which may introduce recall bias and disease misclassification. Second, although survey weights were applied to improve the representativeness of the estimates, a substantial number of participants were excluded because SVR could not be calculated, mainly due to missing DXA-derived appendicular lean mass or visceral fat area data. As these exclusions may not have occurred at random, residual selection bias cannot be ruled out. Third, because this study is cross-sectional, causal inference is not possible and reverse causation cannot be excluded; whether higher SVR directly lowers cardiovascular risk remains uncertain. Fourth, although DXA is among the reference standards for body-composition assessment, its precision may be affected by body habitus and participant positioning. Fifth, despite broad adjustment for potential confounders, residual and unmeasured confounding cannot be ruled out. Future studies should employ prospective designs to validate these findings and to delineate heterogeneity in the association between SVR and cardiovascular risk across populations, thereby elucidating potential biological mechanisms. In parallel, intervention research should examine whether dietary and lifestyle modifications can improve SVR and, in turn, reduce cardiovascular risk. In sum, our study supports consideration of integrated body-composition metrics in clinical assessment and offers new insights and directions for subsequent research. Conclusion In summary, higher SVR was associated with lower odds of composite CVD. This inverse association was mainly observed for HF, CHD, and MI, whereas the findings for AP and stroke were attenuated after full adjustment, suggesting heterogeneity across CVD subtypes. These findings support a potential association between integrated body composition and cardiovascular health, but the clinical utility of SVR requires confirmation in prospective studies. What is already known on this subject? Previous studies have shown that lower muscle mass and greater visceral adiposity are each associated with higher cardiovascular risk, and that composite muscle–fat phenotypes such as SO may also be related to CVD. However, findings have been inconsistent because prior studies used heterogeneous definitions and indicators. What this study adds? To our knowledge, this is the first study to examine the association between SVR and overall CVD, as well as major CVD subtypes, in a nationally representative U.S. population. Higher SVR was associated with lower odds of composite CVD and several major subtypes, particularly HF, CHD, and MI. Nonlinear and subgroup analyses further suggested that the association between SVR and CVD differed across outcomes and appeared more pronounced among participants with overweight/obesity and those with moderate income. Supplementary Information Supplementary material 1. Supplementary material 1.